FDA Files Consent Decree Against Medtronic and CEO Omar Ishrak

By MedTech Intelligence Staff
No Comments

Medtronic repeatedly fails to correct manufacturing violations related to its Synchromed II Implantable Infusion Pump Systems.

FDA filed a consent decree against Medtronic, CEO Omar Ishrak and Thomas Tefft, SVP and president of the neuromodulation unit at the company for “repeatedly failing to correct violations” that occurred at Medtronic’s neuromodulation facilities in Columbia Heights, Minnesota involving the manufacture of Synchromed II Implantable Infusion Pump Systems.

As a result of the decree, which cites violations in the QSR, Medtronic is required to stop manufacturing, designing and distributing Synchromed II infusion pumps and cannot resume such activity until it receives permission from FDA. The company must also retain a third-party expert to assist in developing and submitting plans to correct the violations.

“The FDA expects that all patients will be treated with safe, effective and high-quality medical devices,” said Jan Welch, acting director of the Office of Compliance in the FDA’s Center for Devices and Radiological Health in an agency release. “We will continue to stop distribution of devices made by firms that fall short of regulatory requirements.”

Between 2006 and 2013, Medtronic received three warning letters following inspections conducted at the facilities. The company was cited for major violations: “inadequate processes for identifying, investigating, and correcting quality problems with the Synchromed II Implantable Infusion Pump Systems; failure to document design changes; and failure to ensure that finished products meet design specifications,” according to FDA.

Related Articles

  • FDA Updates List of Recognized Standards

    The agency has said the new standards are meant to reduce the risk of unintended connections between enteral and non-enteral devices.

  • Dr. Christopher Joseph Devine, President, Devine Guidance International

    Consent decrees are expensive. Remember, consent decree and the resulting actions are driven by the courts and all bets are off in regards to when normal business operations will return, if ever. If the process of paying the third-party consultants…

  • Medtronic Posts Higher-Than-Expected Q3 Profits

    The company’s heart devices such as implantable defibrillators, artificial valves and devices to treat atrial fibrillation, contributed to a 5 percent increase in sales in the cardiac and vascular business, its largest unit.

  • Dr. Christopher Joseph Devine, President, Devine Guidance International

    FDA recently ordered a manufacturer of automated endoscope reprocessors to recall product following a consent decree from 2007.

Leave a Reply

Your email address will not be published. Required fields are marked *

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

If you agree to these terms, please click here.